Everest Medicines (SEHK:1952) Wins China Approval As CARDAMYST Puts Valuation Back In Focus
China approves CARDAMYST, putting Everest Medicines in focus
Everest Medicines (SEHK:1952) just cleared a major hurdle in China, with regulators approving CARDAMYST for at home treatment of acute paroxysmal supraventricular tachycardia episodes in adults.
Despite the regulatory win, Everest Medicines shares closed at HK$31.22 after a 1 day share price return that declined 5.5%. However, the 30 day and 90 day share price returns of 10.1% and 13.9% suggest momentum has been building off a weaker year to date picture and a 1 year total shareholder return that fell 48.1%. The 3 year total shareholder return is up 78.4%, but the 5 year total shareholder return is still down 50.8%.
Seize the momentum around Everest Medicines and this latest approval by scanning a curated set of 616 high quality undiscovered gems in healthcare and beyond.Everest Medicines now trades well below both analyst targets and one intrinsic value estimate. After the CARDAMYST approval and the recent share pullback, where might a sensible fair value range for this stock reasonably be considered?
Most Popular Narrative: 26% Undervalued
On the most followed view, Everest Medicines screens as undervalued, with a fair value of HK$42.18 against the last close at HK$31.22, which puts CARDAMYST into a broader pipeline story built around kidney and autoimmune assets.
The company's robust and diversified pipeline, spanning mRNA vaccines, in vivo CAR-T, and novel autoimmune therapies, with multiple assets moving toward late-stage trials, positions Everest to benefit from global moves toward precision and targeted medicines, driving long-term revenue streams and earnings growth from innovative products.
Want to see what underpins that confidence in Everest Medicines? The narrative leans on steep revenue expansion, a sharp swing into profitability, and a future earnings multiple that must justify a higher HK$ valuation without relying on today’s losses.
Result: Fair Value of HK$42.18 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
Still, Everest Medicines leans heavily on a few key therapies, and any setback in reimbursement or clinical trial outcomes could quickly challenge this undervaluation story.
Find out about the key risks to this Everest Medicines narrative.
Next Steps
If the mixed optimism and concern around Everest Medicines feels familiar, treat that as your cue to move quickly and review the numbers yourself. Examine both sides of the story using the 4 key rewards and 1 important warning sign.
Ready for more ideas beyond Everest Medicines?
Do not stop at a single stock. Broaden your watchlist with a few focused screens that surface different types of opportunities before others move first.
- Target potential mispricings by reviewing a tight shortlist of companies that score well on valuation and quality using the 249 high quality undervalued stocks.
- Prioritise resilience by scanning the 306 resilient stocks with low risk scores and filter for businesses with metrics that may better suit a more cautious investing style.
- Hunt for future standouts by working through a curated 616 high quality undiscovered gems that many investors may not be watching yet.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com